PPV

EQS-News: Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Retrieved on: 
Mercredi, mars 13, 2024

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Key Points: 
  • Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
    The issuer is solely responsible for the content of this announcement.
  • Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic
    Dr. Jay Wohlgemuth, former Chief Medical & Scientific Officer of Quest Diagnostics and Dr. Ray Tabibiazar, a seasoned industry executive, to lead collaboration
    BERKELEY, US – MAINZ, Germany – March 5, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today a partnership with Trusted Health Advisors (THA), a market leader in supporting the U.S. launches and management of commercial programs for diagnostic products.
  • In the U.S., Mainz Biomed is in final regulatory planning stages of ReconAAsense clinical trial to seek Premarket Approval (PMA) for its next generation diagnostic test.
  • The Company currently commercializes its first-generation test in Europe and in select international territories through its flagship product ColoAlert® via partnerships with third-party laboratories.

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Retrieved on: 
Mardi, mars 5, 2024

In the U.S., Mainz Biomed is in final regulatory planning stages of ReconAAsense clinical trial to seek Premarket Approval (PMA) for its next generation diagnostic test.

Key Points: 
  • In the U.S., Mainz Biomed is in final regulatory planning stages of ReconAAsense clinical trial to seek Premarket Approval (PMA) for its next generation diagnostic test.
  • The Company currently commercializes its first-generation test in Europe and in select international territories through its flagship product ColoAlert® via partnerships with third-party laboratories.
  • “Detecting AA lesions allows for early intervention and significantly increases the chance of successful treatment and survival.
  • The study’s primary objectives include calculating sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) in average-risk subjects for CRC and AA.

Modiv Industrial Announces Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Lundi, mars 4, 2024

Modiv Industrial, Inc. (“Modiv Industrial”, “Modiv”, the “Company”, “we” or “our”) (NYSE:MDV), the only public REIT exclusively focused on acquiring industrial manufacturing real estate, today announced operating results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • Modiv Industrial, Inc. (“Modiv Industrial”, “Modiv”, the “Company”, “we” or “our”) (NYSE:MDV), the only public REIT exclusively focused on acquiring industrial manufacturing real estate, today announced operating results for the fourth quarter and full year ended December 31, 2023.
  • Fourth quarter revenue of $12.3 million increased $2.3 million year-over-year, or 23%, excluding the 2022 lease termination fee.
  • Fourth quarter AFFO of $4.5 million, or $0.40 per diluted share, exceeding street expectations by $0.05 per share.
  • January 31, 2024, completed the stock distribution of Generation Income Properties, Inc. (NASDAQ: GIPR), common stock to the stockholders of Modiv Industrial.

Endeavor Releases Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Mercredi, février 28, 2024

“2023 was a transformational year for Endeavor as we strengthened our positions in sports and entertainment through many of our industry-leading assets,” said Ariel Emanuel, CEO, Endeavor.

Key Points: 
  • “2023 was a transformational year for Endeavor as we strengthened our positions in sports and entertainment through many of our industry-leading assets,” said Ariel Emanuel, CEO, Endeavor.
  • At December 31, 2023, cash and cash equivalents totaled $1.167 billion, compared to $1.338 billion at September 30, 2023.
  • Total debt was $5.028 billion at December 31, 2023, compared to $5.046 billion at September 30, 2023.
  • Endeavor will host an audio webcast to discuss its results and provide a business update at 5 a.m. PT / 8 a.m.

Enable Biosciences Publishes Study Revealing ADAP Technology's Improved Accuracy in T1D Risk Prediction

Retrieved on: 
Mardi, février 13, 2024

Detailed findings are presented in the article "Advances in risk predictive performance of pre-symptomatic type 1 diabetes via the multiplex Antibody-Detection-by-Agglutination-PCR (ADAP) assay," published in Frontiers of Endocrinology.

Key Points: 
  • Detailed findings are presented in the article "Advances in risk predictive performance of pre-symptomatic type 1 diabetes via the multiplex Antibody-Detection-by-Agglutination-PCR (ADAP) assay," published in Frontiers of Endocrinology.
  • This pivotal study underscores the ADAP assay's ability to detect islet autoantibodies, which are indicative of a high risk of progression to clinical T1D.
  • Dr. Jason Tsai, PhD, CTO of Enable Biosciences, elaborates on the significance of the findings: "These study results reinforce the strength of our ADAP technology in early T1D detection.
  • For more insights into Enable Biosciences and the impact of their ADAP technology, please visit www.enablebiosciences.com .

Fubo Makes Strategic Investment in BKFC, Will Stream BKFC 57 Live Event on February 2

Retrieved on: 
Vendredi, janvier 26, 2024

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240126376160/en/
    The strategic investment expands the companies’ current partnership, which includes live distribution rights on Fubo Sports, Fubo’s FAST (free ad-supported streaming TV) linear network, and Pay-Per-View (PPV).
  • Through the expanded partnership, Fubo will stream select BKFC’s live events, including BKFC 57 on February 2, 2024, live from the Seminole Hard Rock Hotel and Casino in Hollywood, FL.
  • “Fubo is committed to bringing consumers an aggregated content experience that includes the widest choice of live sports programming,” said Gandler.
  • “The singularity of bare knuckle fighting has already made BKFC an important strategic partner for our Fubo Sports linear channel.

EQS-News: Mainz Biomed Provides Year-End Corporate Review 2023

Retrieved on: 
Samedi, janvier 13, 2024

Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.

Key Points: 
  • Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.
  • During the year, Mainz Biomed launched commercial operations in Spain, Portugal, Romania, Poland, the United Kingdom, and Israel.
  • Mainz Biomed provides education for both the employee and physician regarding the ColoAlert® results and CRC, as well as recommendations for next steps.
  • During the year, Mainz Biomed continued to enhance its team with an emphasis on commercial additions given ColoAlert®’s rapid expansion in international markets.

Mainz Biomed Provides Year-End Corporate Review 2023

Retrieved on: 
Mardi, janvier 9, 2024

Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.

Key Points: 
  • Throughout 2023, Mainz Biomed executed its differentiated commercial plan of partnering with third-party laboratories for test kit processing versus the traditional methodology of operating a single facility.
  • During the year, Mainz Biomed launched commercial operations in Spain, Portugal, Romania, Poland, the United Kingdom, and Israel.
  • Mainz Biomed provides education for both the employee and physician regarding the ColoAlert® results and CRC, as well as recommendations for next steps.
  • During the year, Mainz Biomed continued to enhance its team with an emphasis on commercial additions given ColoAlert®’s rapid expansion in international markets.

DermTech Announces Positive Topline Results From Trust 2 Study Evaluating the DermTech Melanoma Test (DMT)

Retrieved on: 
Lundi, janvier 8, 2024

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported positive topline results from its Trust 2 Study, which evaluated the foundational gene expression assay component of the DermTech Melanoma Test (DMT) in a real-world clinical setting.

Key Points: 
  • DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported positive topline results from its Trust 2 Study, which evaluated the foundational gene expression assay component of the DermTech Melanoma Test (DMT) in a real-world clinical setting.
  • The Trust 2 Study results demonstrated an NPV of 99.7% for the foundational gene expression assay component of the DMT.
  • The Trust 2 Study results also included a sensitivity of 95.8%, a specificity of 69.4% and a positive predictive value (PPV) of 13.4%.
  • The Trust 2 Study results further validate the 99% NPV observed in a similar real-world study (Trust 1) published in 2021, which evaluated the tested lesions of more than 1,500 patients.

Bionano Announces Publication of Largest Prospective Prenatal Study Comparing OGM to Chromosomal Microarray Analysis and Karyotyping

Retrieved on: 
Mardi, décembre 26, 2023

SAN DIEGO, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication covering the largest independent prospective prenatal study comparing optical genome mapping (OGM) to a combined workflow of chromosomal microarray analysis (CMA) and karyotyping (KT). The study highlighted OGM’s high analytical concordance with the combined workflow of CMA and KT, and its ability to detect novel pathogenic structural variants (SVs) missed by those methods. The study also highlighted OGM’s potential to provide additional information about SVs and copy number variants (CNVs) compared to CMA and KT.

Key Points: 
  • The study also highlighted OGM’s potential to provide additional information about SVs and copy number variants (CNVs) compared to CMA and KT.
  • Researchers used 200 unique prospective prenatal samples with soft markers (including increased nuchal translucency, nasal bone hypoplasia and mild ventriculomegaly, and structural anomalies) for the study.
  • “The use of OGM for the analysis of prenatal samples is an area where we believe our workflow can have tremendous global impact.
  • We believe this study marks a milestone in the Chinese prenatal research market as it includes the largest sample size to date for an independent prenatal study using OGM.